Abbott Laboratories
ABT
$100.68
+1.87%
Abbott Laboratories is a diversified healthcare company that manufactures and markets cardiovascular and diabetes devices, nutritional products, diagnostic equipment, and branded generic drugs. As a global leader in medical devices and diagnostics, Abbott derives roughly 60% of its sales outside the United States, giving it a distinct competitive advantage in emerging markets. The current investor narrative centers on the company's reduced 2026 profit outlook, which overshadowed a solid first-quarter earnings beat and has driven the stock down over 30% in the past year, raising debates about near-term headwinds versus long-term value. Recent news highlights Abbott's 54-year dividend growth streak and strategic acquisitions, positioning it as a potential turnaround story for patient investors.…
ABT
Abbott Laboratories
$100.68
Related headlines
ABT 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Abbott Laboratories's 12-month outlook, with a consensus price target around $116.54 and implied upside of +15.8% versus the current price.
Average Target
$116.54
0 analysts
Implied Upside
+15.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$92 - $135
Analyst target range
Abbott is covered by 24 analysts, with a consensus recommendation of 'Buy' (mean recommendation 1.67 on a 1-5 scale where 1 is Strong Buy). The average target price is $116.54, implying approximately 30.6% upside from the current price of $89.27. The distribution leans strongly bullish, with no sell ratings and a majority of buy or outperform ratings. Recent ratings from Evercore ISI, Piper Sandler, BTIG, Barclays, Stifel, Benchmark, RBC Capital, and Oppenheimer have all maintained positive stances, indicating sustained institutional confidence despite the stock's decline. The target price range spans from a low of $92.00 to a high of $135.00. The low target of $92.00 suggests only 3.1% upside, implying some analysts see limited near-term catalysts, while the high target of $135.00 implies 51.3% upside, reflecting optimism about a recovery in medical device sales and margin expansion. The wide spread ($43) indicates significant uncertainty about the pace of the turnaround. The consensus EPS estimate for the current fiscal year is $8.34, which, if achieved, would put the forward P/E at roughly 10.7x, a compelling valuation if the company can deliver.
Drowning in data?
Find the real signal!
Bulls vs Bears: ABT Investment Factors
Abbott Laboratories presents a classic value-versus-momentum dilemma. On the bull side, the forward P/E of 14.7x is compelling, the dividend growth streak is unmatched, and analyst consensus points to 30.6% upside. On the bear side, the trailing P/E premium, declining margins, and reduced 2026 guidance have driven a 32% stock decline. The single most important tension is whether the earnings recovery priced into the forward P/E materializes: if Abbott delivers EPS near the $8.34 consensus, the stock is deeply undervalued; if headwinds persist, the premium on current earnings could compress further. Currently, the evidence slightly favors the bulls given the valuation support and strong analyst backing, but the near-term trend remains bearish.
Bullish
- Compelling forward valuation: The forward P/E of 14.7x is near the lower end of its historical range and well below the sector average of ~22x, implying significant undervaluation if earnings recover as expected. Consensus EPS estimate of $8.34 for the current fiscal year supports this view.
- Strong dividend growth streak: Abbott has increased its dividend for 54 consecutive years and declared its 409th consecutive quarterly dividend, demonstrating exceptional financial stability and commitment to shareholder returns. The current dividend yield is 1.88%.
- Diversified revenue stream: With roughly 60% of sales outside the U.S. and four major business segments (Medical Devices, Diagnostics, Nutrition, Pharmaceuticals), Abbott is well-positioned to weather regional downturns. Medical Devices revenue of $5.539 billion in Q1 2026 grew 7.8% YoY.
- Analyst consensus bullish: 24 analysts rate the stock a consensus 'Buy' with a mean recommendation of 1.67 (1=Strong Buy). The average price target of $116.54 implies 30.6% upside from the current price of $89.27, with no sell ratings.
Bearish
- Reduced 2026 profit outlook: Abbott cut its 2026 profit guidance, which overshadowed a Q1 earnings beat and triggered a sharp sell-off. The stock has declined 32.1% over the past year, significantly underperforming the S&P 500's gain of 20.9%.
- Trailing P/E premium to peers: The trailing P/E of 33.5x is 52% above the sector average of ~22x, suggesting the stock is expensive on current earnings. This premium may compress if the expected earnings recovery is delayed.
- Declining profitability margins: Operating margin fell from 19.6% in Q4 2025 to 16.5% in Q1 2026, and net margin dropped from 15.5% to 9.6% over the same period. This margin compression signals rising costs or competitive pressure.
- Sustained downtrend: The stock is in a clear downtrend, trading at 65% of its 52-week range and below all major moving averages. The 3-month relative strength of -12.8% versus the S&P 500 confirms continued underperformance.
ABT Technical Analysis
Abbott is in a sustained downtrend, with the stock price declining 32.1% over the past year compared to the S&P 500's gain of 20.9%. The current price of $89.27 sits at 65% of its 52-week range (low $81.97, high $137.49), indicating the stock is near the bottom of its range and suggesting a potential value opportunity, though the trend remains bearish. The 1-year relative strength of -53.0% versus the S&P underscores significant underperformance. Short-term momentum shows a mixed picture: the 1-month price change is +0.7%, while the 3-month change is -6.5%, indicating a deceleration in the pace of decline but no clear reversal. The 1-month relative strength of +0.1% versus the S&P suggests slight outperformance recently, but the 3-month relative strength of -12.8% confirms the broader downtrend. The divergence between the 1-month stabilization and the 1-year decline could signal a potential bottoming process, but confirmation is needed. Key support is at the 52-week low of $81.97, and resistance is at the 52-week high of $137.49. A breakdown below $81.97 would signal further downside, while a breakout above $137.49 would indicate a trend reversal. The stock's beta of 0.607 implies it is 39% less volatile than the market, meaning it tends to decline less than the S&P during selloffs but also rallies less during uptrends, which is consistent with its defensive healthcare profile.
Beta
0.61
0.61x market volatility
Max Drawdown
-40.2%
Largest decline past year
52-Week Range
$82-$137
Price range past year
Annual Return
-16.5%
Cumulative gain past year
| Period | ABT Return | S&P 500 |
|---|---|---|
| 1m | +13.8% | +0.3% |
| 3m | +4.0% | +4.7% |
| 6m | -17.3% | +7.5% |
| 1y | -16.5% | +18.4% |
| ytd | -18.9% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ABT Fundamental Analysis
Abbott's revenue trajectory remains positive but is decelerating. In Q1 2026, revenue grew 7.8% year-over-year to $11.164 billion, following Q4 2025 revenue of $11.459 billion and Q3 2025 revenue of $11.369 billion. The growth is driven by Medical Devices ($5.539 billion) and Diagnostic Products ($6.2 billion), while Nutritional Products ($2.017 billion) and Established Pharmaceuticals ($1.426 billion) provide steady contributions. However, the company cut its 2026 profit outlook, signaling that revenue growth may face headwinds from currency and competitive pressures. The company is profitable with net income of $1.077 billion in Q1 2026, though this is down from $1.776 billion in Q4 2025. Gross margin remains healthy at 56.3% in Q1 2026, slightly below the 57.0% in Q4 2025, indicating stable pricing power. Operating margin was 16.5% in Q1 2026, down from 19.6% in Q4 2025, reflecting higher operating expenses. Net margin of 9.6% in Q1 2026 is below the 15.5% in Q4 2025, but the company maintains strong profitability relative to industry peers. Abbott's balance sheet is solid with a debt-to-equity ratio of 0.29, indicating low leverage. Free cash flow was $916 million in Q1 2026, down from $2.626 billion in Q4 2025, but the trailing twelve-month free cash flow stands at $7.378 billion, providing ample coverage for dividends and investments. The current ratio of 1.58 suggests adequate liquidity, and ROE of 12.5% reflects efficient capital use.
Quarterly Revenue
$11.2B
2026-03
Revenue YoY Growth
+7.8%
YoY Comparison
Gross Margin
56.3%
Latest Quarter
Free Cash Flow
$7.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ABT Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 33.5x, while the forward P/E is 14.7x, implying the market expects significant earnings growth in the coming year. The large gap between trailing and forward P/E suggests that the current earnings are depressed (likely due to one-time items or cyclical factors), and the market is pricing in a recovery. Compared to the industry (Medical - Devices), Abbott's trailing P/E of 33.5x is above the sector average of approximately 22x, representing a 52% premium. This premium may be justified by Abbott's diversified business model, strong margins, and consistent dividend growth, but it also reflects the market's expectation of a rebound. Historically, Abbott's trailing P/E has ranged from 21x to 46x over the past five years. The current 33.5x is near the middle of that range, suggesting it is not excessively overvalued relative to its own history. However, the forward P/E of 14.7x is near the lower end of its historical forward range, indicating that the stock may be undervalued if earnings materialize as expected.
PE
33.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 21x~47x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Abbott's net income declined from $1.776 billion in Q4 2025 to $1.077 billion in Q1 2026, a 39% drop, while free cash flow fell from $2.626 billion to $916 million over the same period. Operating margin contracted from 19.6% to 16.5%, indicating rising costs that could pressure profitability if revenue growth slows. The debt-to-equity ratio of 0.29 is manageable, but the reliance on continued growth to justify the forward P/E of 14.7x creates risk if earnings disappoint.
Market & Competitive Risks: The stock's trailing P/E of 33.5x represents a 52% premium to the sector average, making it vulnerable to multiple compression if growth expectations are not met. With a beta of 0.607, Abbott is less sensitive to macro swings, but the 32% decline over the past year shows it is not immune to company-specific shocks. Competitive pressures in medical devices and diagnostics could erode market share, while regulatory changes in healthcare could impact pricing.
Worst-Case Scenario: If Abbott fails to deliver on its earnings recovery and the forward P/E expands to reflect continued weakness, the stock could fall to its 52-week low of $81.97, representing a potential loss of 8.2% from the current price of $89.27. In a more severe scenario, if the company cuts guidance further or faces a major product setback, the stock could test the $70 level, implying a 21.6% downside. The historical max drawdown of -40.21% suggests that losses could be deeper in a prolonged downturn.
